Rockefeller Capital Management LP has $3.19M holdings in Laboratory Co. of America Holdings (NYSE:LH)

Rockefeller Capital Management LP raised its stake in shares of Laboratory Co. of America Holdings (NYSE:LH – Get Rating ) by 36.8% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,580 shares of the medical research company’s stock after buying an additional 4,189 shares during the period. Rockefeller Capital Management LP’s holdings in Laboratory Co. of America was worth $3,190,000 at the end of the most recent quarter.

→ Is this the end of capitalism? (From Porter & Company)

Several other large investors have also recently bought and sold shares in the company. Vanguard Group Inc. raised its position in Laboratory Co. of America by 1.0% during the first quarter. Vanguard Group Inc. now owns 10,859,128 shares of the medical research company’s stock valued at $2,863,118,000 after buying an additional 106,063 shares during the period. JPMorgan Chase & Co. raised its position in Laboratory Co. of America by 45.9% during the second quarter. JPMorgan Chase & Co. now owns 1,904,199 shares of the medical research company’s stock valued at $446,269,000 after buying an additional 598,645 shares during the period. FMR LLC raised its stake in Laboratory Co. of America by 3.6% in the second quarter. FMR LLC now owns 1,365,964 shares of the medical research company’s stock valued at $320,128,000 after buying an additional 47,502 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in Laboratory Co. of America by 11.5% in the second quarter. UBS Asset Management Americas Inc. now owns 1,205,517 shares of the medical research company’s stock valued at $282,525,000 after buying an additional 124,119 shares in the last quarter. Finally, Veritas Investment Partners UK Ltd increased its stake in Laboratory Co. of America by 17.3% in the second quarter. Veritas Investment Partners UK Ltd. now owns 945,944 shares of the medical research company’s stock valued at $221,723,000 after buying an additional 139,269 shares in the last quarter. 89.70% of the share is owned by institutional investors and hedge funds.

Changes in analyst ratings

A number of research analysts have commented on the company. Credit Suisse Group decreased their target price on Laboratory Co. of America from $308.00 to $305.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 23rd. Morgan Stanley raised their price target on Laboratory Co. of America from $290.00 to $303.00 and gave the stock an “overweight” rating in a research note on Friday, January 6th. Mizuho decreased their price objective on Laboratory Co. of America from $296.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, November 3rd. William Blair reiterated an “outperform” rating on shares of Laboratory Co. of America in a research note on Thursday, October 27th. Finally, Citigroup downgraded Laboratory Co. of America from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $275.00 to $250.00 in a research note on Monday, December 12th. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $269.13.

Laboratory Co. of America increased by 0.9%

Laboratory Co. of America stock opened at $257.83 on Tuesday. The company has a 50 day moving average price of $238.98 and a two hundred day moving average price of $234.34. The company has a quick ratio of 1.55, a current ratio of 1.73 and a debt-to-equity ratio of 0.54. The stock has a market cap of $22.84 billion, a price-to-earnings ratio of 13.75 and a beta of 1.05. Laboratory Co. of America Holdings has a 12 month low of $200.32 and a 12 month high of $290.20.

Laboratory Co. of America (NYSE:LH – Get Rating ) last released its earnings results on Thursday, October 27th. The medical research company reported $4.68 earnings per share. Laboratory Co. of America had a return on equity of 20.33% and a net margin of 11.51%. The company had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.79 billion. In the same period the previous year, the company had earnings of USD 6.82 per share. The company’s quarterly revenue fell by 11.2% year-on-year. As a group, equities analysts predict that Laboratory Co. of America Holdings will post 19.83 EPS for the current year.

Laboratory Co. of America announces dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 13th. Investors of record on Thursday, February 23rd will be issued a dividend of $0.72 per share. The ex-dividend date for this dividend is Wednesday, February 22nd. This represents an annualized dividend of $2.88 and a yield of 1.12%. Laboratory Co. of America’s dividend yield is 15.36%.

Insider activity at Laboratory Co. of America

In related news, EVP Mark S. Schroeder sold 1,116 shares of the firm’s stock in a transaction on Tuesday, November 8th. The stock was sold at an average price of $232.67, for a total transaction of $259,659.72. Following the completion of the sale, the executive vice president now directly owns 6,687 shares of the company’s stock, valued at approximately $1,555,864.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC website. Insiders own 0.31% of the company’s shares.

Laboratory Co. of America Company Profile

(Get rating)

Laboratory Corporation of America Holdings operates as a global life sciences company, providing vital information to help physicians, hospitals, pharmaceutical companies, researchers and patients make clear and safe decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD).

Read more

Want to see what other hedge funds have LH? Visit HoldingsChannel.com for the latest 13F filings and insider trades for Laboratory Co. of America Holdings (NYSE:LH – Get Rating).

Institutional Ownership by Quarter of Laboratory Co.  of America (NYSE:LH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat editorial staff prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Laboratory Co. of America, you want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market catches on… and Laboratory Co. of America was not on the list.

While Laboratory Co. of America currently has a “Moderate Buy” rating among analysts, top rated analysts believe these five stocks are better buys.

See the five stocks here

10 Best Cheap Stocks to Buy Now
Rockefeller Capital Management LP has $3.19M holdings in Laboratory Co. of America Holdings (NYSE:LH)

Leave a Reply

Your email address will not be published.

Scroll to top